Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?

Literature DB >> 23975607

Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?

Ignacio Bernabeu¹, Felipe F Casanueva.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2013 PMID： 23975607 DOI： 10.1007/s12020-013-9914-1

Source DB: PubMed Journal: Endocrine ISSN： 1355-008X Impact factor: 3.633

× No keyword cloud information.

13 in total

1. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.

Authors: Judith Korner; Janet Lo; Pamela U Freda; Sharon L Wardlaw
Journal: Obes Res Date: 2003-02

2. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

Authors: Felipe F Casanueva; Mark E Molitch; Janet A Schlechte; Roger Abs; Vivien Bonert; Marcello D Bronstein; Thierry Brue; Paolo Cappabianca; Annamaria Colao; Rudolf Fahlbusch; Hugo Fideleff; Moshe Hadani; Paul Kelly; David Kleinberg; Edward Laws; Josef Marek; Maurice Scanlon; Luis G Sobrinho; John A H Wass; Andrea Giustina
Journal: Clin Endocrinol (Oxf) Date: 2006-08 Impact factor: 3.478

3. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.

Authors: Katarina Berinder; Thomas Nyström; Charlotte Höybye; Kerstin Hall; Anna-Lena Hulting
Journal: Pituitary Date: 2011-09 Impact factor: 4.107

4. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.

Authors: Serap Soytac Inancli; Alper Usluogullari; Yusuf Ustu; Sedat Caner; Abbas Ali Tam; Reyhan Ersoy; Bekir Cakir
Journal: Endocrine Date: 2012-12-12 Impact factor: 3.633

5. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.

Authors: Juan Jesús Carrero; John Kyriazis; Alper Sonmez; Ioannis Tzanakis; Abdul Rashid Qureshi; Peter Stenvinkel; Mutlu Saglam; Kostas Stylianou; Halil Yaman; Abdullah Taslipinar; Abdulgaffar Vural; Mahmut Gok; Mujdat Yenicesu; Eugene Daphnis; Mahmut Ilker Yilmaz
Journal: Clin J Am Soc Nephrol Date: 2011-12-22 Impact factor: 8.237

Review 6. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency.

Authors: K Dorshkind; N D Horseman
Journal: Endocr Rev Date: 2000-06 Impact factor: 19.871

4. Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.

Authors: Michael Ezrokhi; Yahong Zhang; Shuqin Luo; Anthony H Cincotta
Journal: Int J Mol Sci Date: 2021-06-07 Impact factor: 5.923

4 in total

Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?

1. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.

2. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

3. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.

4. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.

5. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.

Review 6. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency.

7. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.

8. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality.

Review 9. Focus on prolactin as a metabolic hormone.

Review 10. Adipocyte prolactin: regulation of release and putative functions.

Review 1. Screening for hormonal, monogenic, and syndromic disorders in obese infants and children.

Review 2. The risks of overlooking the diagnosis of secreting pituitary adenomas.

3. Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis.

4. Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.